Advertisement

Drugs

, Volume 63, Issue 24, pp 2709–2723 | Cite as

What is the Role of NSAIDs in Pre-emptive Analgesia?

  • E. Andrew Ochroch
  • Issam A. Mardini
  • Allan Gottschalk
Current Opinion

Abstract

NSAIDs inhibit the cyclo-oxygenase enzymes, and decrease peripheral and central prostaglandin production. In addition to reducing the inflammation that accompanies tissue injury, decreasing prostaglandin production attenuates the response of the peripheral and central components of the nervous system to noxious stimuli. Such a reduction in the response to pain can reduce the peripheral and central sensitisation induced by noxious stimuli, and reduce the pain experienced in response to subsequent noxious stimuli. These properties would seem to make NSAIDs ideal drugs to use in a pre-emptive fashion, where analgesics are administered prior to a noxious stimulus, such as surgery, with the expectation that reduction in peripheral and central sensitisation will lead to a decrease of pain.

However, the available perioperative trials of pre-emptive NSAID use have yielded modest or equivocal results, and these may be due, in part, to controversy associated with the definition of pre-emptive analgesia and how to conduct the corresponding clinical trials. Although NSAIDs may have a limited ability by themselves to induce a pre-emptive analgesic effect, the available trials suggest how the perioperative use of these drugs may be made more effective. It is expected that NSAIDs will play an increasing role in multimodal analgesia and pain relief in general.

Keywords

Ketorolac Central Sensitisation Noxious Stimulus Tenoxicam Brief Pain Inventory 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Dr Ochroch is supported by grant K23-HD-040914 from the National Institutes of Health. Dr Mardini is supported by the McCabe Fund. Dr Gottschalk is supported by grant NS41865 from the National Institutes of Health. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Yaksh TL, Dirig DM, Malmberg AB. Mechanism of action of nonsteroidal anti-inflammatory drags. Cancer Invest 1998; 16(7): 509–27PubMedCrossRefGoogle Scholar
  2. 2.
    Katz J. Pre-emptive analgesia: evidence, current status and future directions. Eur J Anaesthesiol Suppl 1995; 10: 8–13PubMedGoogle Scholar
  3. 3.
    Kelly DJ, Ahmad M, Brail SJ. Preemptive analgesia I: physiological pathways and pharmacological modalities [in French]. Can J Anaesth 2001; 48(10): 1000–10PubMedCrossRefGoogle Scholar
  4. 4.
    Rainville P, Duncan GH, Price DD, et al. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science 1997; 277(5328): 968–71PubMedCrossRefGoogle Scholar
  5. 5.
    Kehlet H, Dahl JB. The value of “multimodal” or “balanced” analgesia in postoperative pain treatment. Anesth Analg 1993; 77: 1048–56PubMedCrossRefGoogle Scholar
  6. 6.
    Willis WD. Role of neurotransmitters in sensitization of pain responses. Ann N Y Acad Sci 2001; 933: 142–56PubMedCrossRefGoogle Scholar
  7. 7.
    Church MK, Lowman MA, Robinson C, et al. Interaction of neuropeptides with human mast cells. Int Arch Allergy Appl Immunol 1989; 88(1–2): 70–8PubMedCrossRefGoogle Scholar
  8. 8.
    Cohen RH, Perl ER. Contributions of arachidonic acid derivatives and substance P to the sensitization of cutaneous nociceptors. J Neurophysiol 1990; 64(2): 457–64PubMedGoogle Scholar
  9. 9.
    Melzack R, Coderre TJ, Katz J, et al. Central neuroplasticity and pathological pain. Ann N Y Acad Sci 2001; 933: 157–74PubMedCrossRefGoogle Scholar
  10. 10.
    Levine JD, Fields HL, Basbaum AI. Peptides and the primary afferent nociceptor. J Neurosci 1993; 13(6): 2273–86PubMedGoogle Scholar
  11. 11.
    Holzer P. Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 1988; 24(3): 739–68PubMedCrossRefGoogle Scholar
  12. 12.
    Brain SD, Williams TJ, Tippins JR, et al. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985; 313(5997): 54–6PubMedCrossRefGoogle Scholar
  13. 13.
    Jenkins DW, Feniuk W, Humphrey PP. Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br J Pharmacol 2001; 134(6): 1296–302PubMedCrossRefGoogle Scholar
  14. 14.
    Ottosson A, Edvinsson L. Release of histamine from durai mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 1997; 17(3): 166–74PubMedCrossRefGoogle Scholar
  15. 15.
    Dray A. Inflammatory mediators of pain. Br J Anaesth 1995; 75(2): 125–31PubMedCrossRefGoogle Scholar
  16. 16.
    Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288(5472): 1765–9PubMedCrossRefGoogle Scholar
  17. 17.
    Ossipov MH, Lai J, Malan Jr TP, et al. Spinal and supraspinal mechanisms of neuropathic pain. Ann N Y Acad Sci 2000; 909:12–24PubMedCrossRefGoogle Scholar
  18. 18.
    Treede RD, Magerl W. Multiple mechanisms of secondary hyperalgesia. Prog Brain Res 2000; 129: 331–41PubMedCrossRefGoogle Scholar
  19. 19.
    Herrero JF, Laird JM, Lopez-Garcia JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol 2000; 61(2): 169–203PubMedCrossRefGoogle Scholar
  20. 20.
    McCrory CR, Lindahl SG. Cyclooxygenase inhibition for postoperative analgesia. Anesth Analg 2002; 95(1): 169–76PubMedCrossRefGoogle Scholar
  21. 21.
    Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99(21): 13926–31PubMedCrossRefGoogle Scholar
  22. 22.
    Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001; 107(12): 1491–5PubMedCrossRefGoogle Scholar
  23. 23.
    Svensson CI, Yaksh TL. The spinal phospholipase-cyclooxy-genase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 2002; 42: 553–83PubMedCrossRefGoogle Scholar
  24. 24.
    Yaksh TL. Spinal actions of cyclooxygenase isozyme inhibitors. 9th World Congress on Pain; 2000 Aug 22–27; Vienna. Seattle (WA): IASP Press, 2000: 771–85Google Scholar
  25. 25.
    Malmberg AB, Yaksh TL. Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthe-tized rats. J Neurosci 1995; 15(4): 2768–76PubMedGoogle Scholar
  26. 26.
    Yaksh TL, Malmberg AB. Spinal actions of NSAIDS in blocking spinally mediated hyperalgesia: the role of cyclooxygenase products. Agents Actions Suppl 1993; 41: 89–100PubMedGoogle Scholar
  27. 27.
    Yaksh TL, Dirig DM, Conway CM, et al. The acute antihyper-algesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001; 21(16): 5847–53PubMedGoogle Scholar
  28. 28.
    Dirig DM, Yaksh TL. In vitro prostanoid release from spinal cord following peripheral inflammation: effects of substance P, NMDA and capsaicin. Br J Pharmacol 1999; 126(6): 1333–40PubMedCrossRefGoogle Scholar
  29. 29.
    Dirig DM, Yaksh TL. Spinal synthesis and release of prostanoids after peripheral injury and inflammation. Adv Exp Med Biol 1999; 469: 401–8PubMedCrossRefGoogle Scholar
  30. 30.
    Lorenzo AV, Spector R. The distribution of drugs in the central nervous system. Adv Exp Med Biol 1976; 69: 447–61PubMedCrossRefGoogle Scholar
  31. 31.
    Bannwarth B, Netter P, Lapicque F, et al. Plasma and cerebrospinal fluid concentrations of indomethacin in humans: relationship to analgesic activity. Eur J Clin Pharmacol 1990; 38(4): 343–6PubMedCrossRefGoogle Scholar
  32. 32.
    Bannwarth B, Lapicque F, Pehourcq F, et al. Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. Br J Clin Pharmacol 1995; 40(3): 266–9PubMedCrossRefGoogle Scholar
  33. 33.
    Rice AS, Lloyd J, Bullingham RE, et al. Ketorolac penetration into the cerebrospinal fluid of humans. J Clin Anesth 1993; 5(6): 459–62PubMedCrossRefGoogle Scholar
  34. 34.
    Jolliet P, Simon N, Bree F, et al. Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery. Pharm Res 1997; 14(5): 650–6PubMedCrossRefGoogle Scholar
  35. 35.
    Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001; 41(4): 299–332PubMedCrossRefGoogle Scholar
  36. 36.
    Abram SE, Yaksh TL. Morphine, but not inhalation anesthesia, blocks post-injury facilitation: the role of preemptive suppression of afferent transmission. Anesthesiology 1993; 78(4): 713–21PubMedCrossRefGoogle Scholar
  37. 37.
    Kissin I. Preemptive analgesia: why its effect is not always obvious. Anesthesiology 1996; 84(5): 1015–9PubMedCrossRefGoogle Scholar
  38. 38.
    Kissin I. Preemptive analgesia. Anesthesiology 2000; 93(4): 1138–43PubMedCrossRefGoogle Scholar
  39. 39.
    Kissin I. Preemptive analgesia. In: Devor M, Rowbotham DJ, Wiesenfeld-Hallin Z, editors. How can we make it work? Seattle (WA): IASP Press, 2000: 973–85Google Scholar
  40. 40.
    Katz J. Pre-emptive analgesia: importance of timing. Can J Anaesth 2001; 48(2): 105–14PubMedCrossRefGoogle Scholar
  41. 41.
    Katz J. Preemptive analgesia: where do we go from here? J Pain 2000; 1: 89–92Google Scholar
  42. 42.
    Moiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia. Anesthesiology 2002; 96(3): 725–41PubMedCrossRefGoogle Scholar
  43. 43.
    Hogan QH. No preemptive analgesia: is that so bad? Anesthesiology 2002; 96(3): 526–7PubMedCrossRefGoogle Scholar
  44. 44.
    Kehlet H. Postoperative pain relief: what is the issue? Br J Anaesth 1994; 72(4): 375–8PubMedCrossRefGoogle Scholar
  45. 45.
    Kelly DJ, Ahmad M, Brull SJ. Preemptive analgesia II: recent advances and current trends [in French]. Can J Anaesth 2001; 48(11): 1091–101PubMedCrossRefGoogle Scholar
  46. 46.
    Anonymous. Pain terms: a list with definitions and notes on usage: recommended by the IASP Subcommittee on Taxonomy. Pain 1979; 6 (3): 249Google Scholar
  47. 47.
    Banos JE, Bosch F, Canellas M, et al. Acceptability of visual analogue scales in the clinical setting: a comparison with verbal rating scales in postoperative pain. Methods Find Exp Clin Pharmacol 1989; 11(2): 123–7PubMedGoogle Scholar
  48. 48.
    Carlsson AM. Assessment of chronic pain: I, aspects of the reliability and validity of the visual analogue scale. Pain 1983; 16(1): 87–101PubMedCrossRefGoogle Scholar
  49. 49.
    Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain 1997; 72(1–2): 95–7PubMedCrossRefGoogle Scholar
  50. 50.
    Liu WH, Aitkenhead AR. Comparison of contemporaneous and retrospective assessment of postoperative pain using the visual analogue scale. Br J Anaesth 1991; 67(6): 768–71PubMedCrossRefGoogle Scholar
  51. 51.
    Price DD, McGrath PA, Rafii A, et al. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 1983; 17(1): 45–56PubMedCrossRefGoogle Scholar
  52. 52.
    Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe?: grading pain severity by its interference with function. Pain 1995; 61(2): 277–84PubMedCrossRefGoogle Scholar
  53. 53.
    Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17(2): 197–210PubMedCrossRefGoogle Scholar
  54. 54.
    Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23(2): 129–38PubMedGoogle Scholar
  55. 55.
    Kuch K. Psychological factors and the development of chronic pain. Clin J Pain 2001; 17 (4 Suppl.): S33–8PubMedCrossRefGoogle Scholar
  56. 56.
    Blackburn-Munro GB-MR. Psychological factors and the development of chronic pain. J Neuroendocrinol 2001; 13(12): 1009–23PubMedCrossRefGoogle Scholar
  57. 57.
    McHorney CA, Ware Jr JE, Lu JF, et al. The MOS 36-item Short-Form Health Survey (SF-36): III, tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32(1): 40–66PubMedCrossRefGoogle Scholar
  58. 58.
    McHorney CA, Haley SM, Ware Jr JE. Evaluation of the MOS SF-36 Physical Functioning Scale (PF-10): II, comparison of relative precision using Likert and Rasch scoring methods. J Clin Epidemiol 1997; 50(4): 451–61PubMedCrossRefGoogle Scholar
  59. 59.
    Wagner AK, Gandek B, Aaronson NK, et al. Cross-cultural comparisons of the content of SF-36 translations across 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51(11): 925–32PubMedCrossRefGoogle Scholar
  60. 60.
    Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I, conceptual framework and item selection. Med Care 1992; 30(6): 473–83PubMedCrossRefGoogle Scholar
  61. 61.
    Ware Jr JE, Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995; 33 (4 Suppl.): AS264–79PubMedCrossRefGoogle Scholar
  62. 62.
    Ware Jr JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998; 51(11): 903–12PubMedCrossRefGoogle Scholar
  63. 63.
    Ware Jr JE, Snow KK, Kosinski M, et al. SF-36 health survey: manual and interpretation guide. Lincoln (RI): Quality Metric Inc, 2000Google Scholar
  64. 64.
    Ochroch EA, Gottschalk A, Augostides J, et al. A randomized study of long-term pain and activity during recovery from major thoracotomy using thoracic epidural analgesia. Anesthesiology 2002; 97: 1234–44PubMedCrossRefGoogle Scholar
  65. 65.
    Flath RK, Hicks ML, Dionne RA, et al. Pain suppression after pulpectomy with preoperative flurbiprofen. J Endod 1987; 13(7): 339–47PubMedCrossRefGoogle Scholar
  66. 66.
    Sisk AL, Mosley RO, Martin RP. Comparison of preoperative and postoperative diflunisal for suppression of postoperative pain. J Oral Maxillofac Surg 1989; 47(5): 464–8PubMedCrossRefGoogle Scholar
  67. 67.
    Sisk AL, Grover BJ. A comparison of preoperative and postoperative naproxen sodium for suppression of postoperative pain. J Oral Maxillofac Surg 1990; 48(7): 674–8PubMedCrossRefGoogle Scholar
  68. 68.
    Vogel RI, Desjardins PJ, Major KV. Comparison of presurgical and immediate postsurgical ibuprofen on postoperative periodontal pain. J Periodontol 1992; 63(11): 914–8PubMedCrossRefGoogle Scholar
  69. 69.
    Bridgman JB, Gillgrass TG, Zacharias M. The absence of any pre-emptive analgesic effect for non-steroidal anti-inflammatory drugs. Br J Oral Maxillofac Surg 1996; 34(5): 428–31PubMedCrossRefGoogle Scholar
  70. 70.
    Ashworth HL, Ong C, Seed PT, et al. The influence of timing and route of administration of intravenous ketorolac on analgesia after hand surgery. Anaesthesia 2002; 57(6): 535–9PubMedCrossRefGoogle Scholar
  71. 71.
    Nelson WE, Henderson RC, Almekinders LC, et al. An evaluation of pre- and postoperative nonsteroidal antiinflammatory drugs in patients undergoing knee arthroscopy: a prospective, randomized, double-blinded study. Am J Sports Med 1993; 21(4): 510–6PubMedCrossRefGoogle Scholar
  72. 72.
    Sandin R, Sternlo JE, Stam H, et al. Diclofenac for pain relief after arthroscopy: a comparison of early and delayed treatment. Acta Anaesthesiol Scand 1993; 37(8): 747–50PubMedCrossRefGoogle Scholar
  73. 73.
    Reuben SS, Bhopatkar S, Maciolek H, et al. The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth Analg 2002; 94(1): 55–9PubMedGoogle Scholar
  74. 74.
    Bunemann L, Thorshauge H, Herlevsen P, et al. Analgesia for outpatient surgery: placebo versus naproxen sodium (a nonsteroidal anti-inflammatory drug) given before or after surgery. Eur J Anaesthesiol 1994; 11(6): 461–4PubMedGoogle Scholar
  75. 75.
    Norris A, Un V, Chung F, et al. When should diclofenac be given in ambulatory surgery: preoperatively or postoperatively? J Clin Anesth 2001; 13(1): 11–5PubMedCrossRefGoogle Scholar
  76. 76.
    Nordbladh I, Ohlander B, Bjorkman R. Analgesia in tonsillectomy: a double-blind study on pre and post-operative treatment with diclofenac. Clin Otolaryngol 1991; 16(6): 554–8PubMedCrossRefGoogle Scholar
  77. 77.
    Kokki H, Salonen A. Comparison of pre- and postoperative administration of ketoprofen for analgesia after tonsillectomy in children. Paediatr Anaesth 2002; 12(2): 162–7PubMedCrossRefGoogle Scholar
  78. 78.
    Romsing J, Ostergaard D, Walther-Larsen S, et al. Analgesic efficacy and safety of preoperative versus postoperative ketorolac in paediatric tonsillectomy. Acta Anaesthesiol Scand 1998; 42(7): 770–5PubMedCrossRefGoogle Scholar
  79. 79.
    Salonen A, Kokki H, Tuovinen K. IV ketoprofen for analgesia after tonsillectomy: comparison of pre- and post-operative administration. Br J Anaesth 2001; 86(3): 377–81PubMedCrossRefGoogle Scholar
  80. 80.
    O’Hanlon DM, Thambipillai T, Colbert ST, et al. Timing of pre-emptive tenoxicam is important for postoperative analgesia. Can J Anaesth 2001; 48(2): 162–6PubMedCrossRefGoogle Scholar
  81. 81.
    Colbert ST, O’Hanlon DM, McDonnell C, et al. Analgesia in day case breast biopsy: the value of pre-emptive tenoxicam. Can J Anaesth 1998; 45(3): 217–22PubMedCrossRefGoogle Scholar
  82. 82.
    Chan A, Dore CJ, Ramachandra V. Analgesia for day surgery: evaluation of the effect of diclofenac given before or after surgery with or without bupivacaine infiltration. Anaesthesia 1996; 51(6): 592–5PubMedCrossRefGoogle Scholar
  83. 83.
    Buggy DJ, Wall C, Carton EG. Preoperative or postoperative diclofenac for laparoscopic tubal ligation. Br J Anaesth 1994; 73(6): 767–70PubMedCrossRefGoogle Scholar
  84. 84.
    O’Hanlon JJ, Muldoon T, Lowry D, et al. Improved postoperative analgesia with preoperative piroxicam. Can J Anaesth 1996; 43(2): 102–5PubMedCrossRefGoogle Scholar
  85. 85.
    Cabell CA. Does ketorolac produce preemptive analgesic effects in laparoscopic ambulatory surgery patients? AANA Js 2000; 68(4): 343–9PubMedGoogle Scholar
  86. 86.
    Norman PH, Daley MD, Lindsey RW. Preemptive analgesic effects of ketorolac in ankle fracture surgery. Anesthesiology 2001; 94(4): 599–603PubMedCrossRefGoogle Scholar
  87. 87.
    Fletcher D, Zetlaoui P, Monin S, et al. Influence of timing on the analgesic effect of intravenous ketorolac after orthopedic surgery. Pain 1995; 61(2): 291–7PubMedCrossRefGoogle Scholar
  88. 88.
    Gabbott DA, Cohen AM, Mayor AH, et al. The influence of timing of ketorolac administration on post-operative analgesic requirements following total abdominal hysterectomy. Eur J Anaesthesiol 1997; 14(6): 610–5PubMedCrossRefGoogle Scholar
  89. 89.
    Parke TJ, Lowson SM, Uncles DR, et al. Pre-emptive versus post-surgical administration of ketorolac for hysterectomy. Eur J Anaesthesiol 1995; 12(6): 549–53PubMedGoogle Scholar
  90. 90.
    Castiglione G, Hauf ME, Panascia E, et al. Does the preoperative administration of ketorolac improve postoperative analgesia. Minerva Anestesiol 1997; 63(7–8): 237–43PubMedGoogle Scholar
  91. 91.
    Likar R, Krumpholz R, Mathiaschitz K, et al. The preemptive action of ketoprofen: randomized, double-blind study with gynecologic operations. Anaesthesist 1997; 46(3): 186–90PubMedCrossRefGoogle Scholar
  92. 92.
    Likar R, Krumpholz R, Pipam W, et al. Randomized, double-blind study with ketoprofen in gynecologic patients: preemptive analgesia study following the Brevik-Stubhaug design. Anaesthesist 1998; 47(4): 303–10PubMedCrossRefGoogle Scholar
  93. 93.
    Murphy DF, Medley C. Preoperative indomethacin for pain relief after thoracotomy: comparison with postoperative indomethacin. Br J Anaesth 1993; 70(3): 298–300PubMedCrossRefGoogle Scholar
  94. 94.
    Cronstein BN. Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility. Cleve Clin J Med 2002; 69 Suppl. 1: SI13–9PubMedCrossRefGoogle Scholar
  95. 95.
    Mather LE. Do the pharmacodynamics of the nonsteroidal anti-inflammatory drugs suggest a role in the management of postoperative pain? Drugs 1992; 44 Suppl. 5: 1–12PubMedCrossRefGoogle Scholar
  96. 96.
    Melzack R. The challenge of pain. 2nd ed. New York: Basic Books, 1998Google Scholar
  97. 97.
    Hennekens CHJB. Epidemiology in medicine. Boston (MA): Little, Brown and Co, 1987Google Scholar
  98. 98.
    Dajczman E, Gordon A, Kreisman H, et al. Long-term postthoracotomy pain. Chest 1991; 99(2): 270–4PubMedCrossRefGoogle Scholar
  99. 99.
    Jin F, Chung F. Multimodal analgesia for postoperative pain control. J Clin Anesth 2001; 13(7): 524–39PubMedCrossRefGoogle Scholar
  100. 100.
    Wall PD. The prevention of postoperative pain. Pain 1988; 33(3): 289–90PubMedCrossRefGoogle Scholar
  101. 101.
    Holthusen H, Backhaus P, Boeminghaus F, et al. Preemptive analgesia: no relevant advantage of preoperative compared with postoperative intravenous administration of morphine, ketamine, and clonidine in patients undergoing transperitoneal tumor nephrectomy. Reg Anesth Pain Med 2002; 27(3): 249–53PubMedGoogle Scholar
  102. 102.
    Farrar MW, Lerman J. Novel concepts for analgesia in pediatric surgical patients: cyclo-oxygenase-2 inhibitors, alpha 2-agonists, and opioids. Anesthesiol Clin N Am 2002; 20(1): 59–82CrossRefGoogle Scholar
  103. 103.
    Tverskoy M, Oz Y, Isakson A, et al. Preemptive effect of fentanyl and ketamine on postoperative pain and wound hyperalgesia. Anesth Analg 1994; 78(2): 205–9PubMedCrossRefGoogle Scholar
  104. 104.
    Tverskoy M, Oren M, Vaskovich M, et al. Ketamine enhances local anesthetic and analgesic effects of bupivacaine by peripheral mechanism: a study in postoperative patients. Neurosci Lett 1996; 215(1): 5–8PubMedCrossRefGoogle Scholar
  105. 105.
    Russell MW, Jobes D. What should we do with aspirin, NSAIDs, and glycoprotein-receptor inhibitors? Int Anesthesiol Clin 2002; 40(2): 63–76PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • E. Andrew Ochroch
    • 1
  • Issam A. Mardini
    • 1
    • 2
  • Allan Gottschalk
    • 3
  1. 1.Department of AnesthesiaUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of PharmacologyUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Department of Anesthesiology and Critical Care Medicine, Meyer 8-134Johns Hopkins HospitalBaltimoreUSA

Personalised recommendations